Compare YieldMax AMD Option Income Strategy ETF (AMDY) vs BridgeBio Pharma Inc (BBIO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
YieldMax AMD Option Income Strategy ETF vs BridgeBio Pharma Inc — how do they compare? YieldMax AMD Option Income Strategy ETF trades at $45.12, while BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B). The key difference: BridgeBio Pharma Inc is trading nearer its 52-week high, YieldMax AMD Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.
| AMDY | BBIO | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $59.52 | $90.17 |
52-Week Low | $29.80 | $47.29 |
Market Cap | — | $16.61B |
Enterprise Value | — | $18.16B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMDY trades at $45.61, down 0.93% on the day, with a bearish technical signal from moving averages and neutral oscillators. The ETF has delivered high weekly distributions, with recent dividends ranging from $0.63 to $1.17, but faces concerns over net asset value erosion. Support is seen at $45, with resistance at $47.
The outlook is cautious due to structural NAV erosion risks highlighted by analysts. Investment opportunity lies in high income generation if AMD exhibits gradual volatility, but direct AMD exposure may be preferable for AI-driven upside. Key risks include yield sustainability and dependency on AMD's stock performance.
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About YieldMax AMD Option Income Strategy ETF
AMDY is an active ETF that seeks to generate weekly income by selling call options on AMD stock. It aims to provide investors with high yield while maintaining exposure to the price movements of Advanced Micro Devices.
Read more on AMDY →About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →
